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Sudden deathRecently identiﬁed genetic forms of short QT syndrome (SQTS) are associated with an increased risk of
arrhythmia and sudden death. The SQT3 variant is associated with an amino-acid substitution (D172N) in the
KCNJ2-encoded Kir2.1 K+ channel. In this study, whole-cell action potential (AP) clamp recording from
transiently transfected Chinese Hamster Ovary cells at 37 °C showed marked augmentation of outward Kir2.1
current through D172N channels, associated with right-ward voltage-shifts of peak repolarizing current
during both ventricular and atrial AP commands. Peak outward current elicited by ventricular AP commands
was inhibited by chloroquine with an IC50 of 2.45 μM for wild-type (WT) Kir2.1, of 3.30 μM for D172N-Kir2.1
alone and of 3.11 μM for co-expressedWT and D172N (PN0.05 for all). These ﬁndings establish chloroquine as
an effective inhibitor of SQT3 mutant Kir2.1 channels.
© 2009 Elsevier Inc. Open access under CC BY-NC-ND license.1. IntroductionThe short QT syndrome (SQTS) is linked to abbreviated QT
intervals on the electrocardiogram and to an increased incidence of
cardiac arrhythmias and of sudden death [1]. The SQT3 variant was
identiﬁed in an asymptomatic child with an abnormal electrocardio-
gram and in her father who had a history of presyncopal events and
palpitations [2]. Father and daughter had abbreviated rate-corrected
QT (QTc) intervals of 320 ms and 315 ms respectively, and
programmed electrical stimulation was able to elicit ventricular
ﬁbrillation [2]. Genetic analysis [2] revealed that neither individual
exhibited mutations in KCNH2 or KCNQ1 (associated with SQT1 and
SQT2 variants respectively; [1]), but a single base substitution was
identiﬁed in KCNJ2, giving rise to an aspartate to asparagine
substitution at position 172 (D172N) in the Kir2.1 potassium channel
protein. In humans, Kir2.1 is expressed in both atria and ventricles and
contributes to channels underlying the inwardly rectifying K+ current
IK1 [3]. Patch clamp recordings at ambient temperature showed
augmentation of outward but not inward current through
D172N-Kir2.1 channels, predicted in cell and tissue simulations to
accelerate ventricular repolarization [2].ox).
al Research, Horsham, West
-NC-ND license.For the KCNH2-linked SQT1 variant, the action potential voltage-
clamp (‘AP clamp’) technique has been used to characterize effects of
the SQT1 mutation on ionic current during physiological waveforms
[4,5]. In addition, in vitro and in vivo investigations have also identiﬁed
pharmacological agents that can help restore towards normal the QT
intervals of SQT1 patients (e.g. [6–8]). To date, neither of these
approaches has been applied to the SQT3 D172N mutation. Accord-
ingly, the present study: (i) provides the ﬁrst AP clamp information on
effects of the Kir2.1 mutation, and does so at physiological
temperature; (ii) identiﬁes an effective pharmacological inhibitor of
SQT3 D172N mutant Kir2.1.
2. Methods
2.1. Maintenance of cells expressing WT and D172N-Kir2.1 channels
Wild-type (WT) and mutant (D172N) Kir2.1 (in pSVL expression
vector) were kindly provided by Professor H Matsuda [9]. Chinese
Hamster Ovary (CHO) cells were passaged using a non-enzymatic
agent (Enzyme Free, Chemicon®International) and then maintained
as described previously [5]. They were transiently transfected with
either WTor D172N-Kir2.1 (2 μg of each construct was used) at a ratio
of 4:1 with CD8 (in pIRES; courtesy of Dr I Baró and Dr J Barhanin),
24 h after plating cells out, using Lipofectamine™ LTX (Invitrogen),
according to the manufacturer's instructions. For co-expression of WT
and D172N-Kir2.1 (to mimic the heterozygous condition of the SQT3
proband [2]) cells were transfected with equal amounts of WT and
Fig. 1.WT, WT-D172N and D172N-Kir2.1 during ramp and ventricular AP waveforms. (A) Example traces of WT IKir2.1 (Ai) and D172N IKir2.1 (Aii) elicited by ascending voltage ramp
command, shown in (Aiii) (applied at 3 s intervals) in control and following application of 1 mM BaCl2. (B) Mean current–voltage (I–V) relations for Ba2+-sensitive current for WT,
WT-D172N and D172N Kir2.1 (n=18, 24 and 7 cells respectively). For each cell, currents were normalized to the current at −120 mV to facilitate comparison between the three
channel expression conditions. (⁎⁎⁎Pb0.001 versus WT, ⁎⁎Pb0.01 versus WT,⁎Pb0.05 versus WT, †††Pb0.001 versus D172N, †Pb0.05 versus D172N). (C) Proﬁle of 1 mM Ba2+-
sensitive WT IKir2.1 (Ci), WT-D172N IKir2.1 (Cii) and D172N IKir2.1 (Ciii) (solid traces) during an epicardial ventricular AP command (dash-dotted trace, 1 Hz). Residual capacitative
current transients during the rising phase of the AP command have been blanked for clarity of display. (D) Representative instantaneous I–V relations for WT (Di), WT-D172N (Dii)
and D172N (Diii) current during ventricular AP repolarization (direction of repolarization denoted by arrows). For each cell, currents were normalized to the maximal current during
repolarization and plotted against the corresponding membrane potential from the AP peak to the return to −80 mV. To facilitate comparison between the different channel
expression conditions the WT I–V relation was superimposed (as a grey trace) on the WT-D172N (Dii) and D172N (Diii) I–V plots (black traces).
744 A. El Harchi et al. / Journal of Molecular and Cellular Cardiology 47 (2009) 743–747
745A. El Harchi et al. / Journal of Molecular and Cellular Cardiology 47 (2009) 743–747D172N constructs (cf [2]). Cells were plated onto small sterilised
collagen-coated glass coverslips 6 h after transfection and recordings
were made after at least 24 h incubation at 37 °C. Successfully
transfected cells (positive to CD8) were identiﬁed using Dynabeads®
(Invitrogen).
2.2. Electrophysiological recordings
For whole-cell patch-clamp recording cells were continuously
superfused (at 37 °C) with an external solution containing (in mM):
140 NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10 Glucose and 5 HEPES (titrated to
pH 7.45with NaOH). Patch-pipettes (Corning 7052 glass, AM Systems)
were pulled and heat polished (Narishige MF83) to 2.5–4MΩ; pipette
dialysate contained (in mM): 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP and
10 HEPES (titrated to pH 7.2 using KOH). These solutions are similar to
those used previously to study the KCNH2 SQT1 mutation [5].
Recordings of Kir2.1 current (IKir2.1) were made using an Axopatch
200 ampliﬁer (Axon Instruments) and a CV201 head-stage. Between
70 and 80% of pipette series resistance was compensated. Voltage-
clamp commands were generated using ‘WinWCP’ (John Dempster,
Strathclyde University). Human ventricular and atrial AP waveforms
were generated using established ventricular [10] and atrial [11] cell
models.
2.3. Experimental compounds
Chloroquine-HCl powder (Sigma)was dissolved inMilli-Qwater to
produce an initial stock solution of 50 mM which was diluted to
produce stock solutions ranging down to 300 μM. The Chloroquine-
HCl stock solutions were diluted at least 1:1000-fold with Tyrode's
solution to achieve concentrations stated in the Results. BaCl2 powder
(Sigma) was dissolved in Milli-Q water to produce a stock concentra-
tion of 1 M and the test concentration (1 mM) was produced by a
1:1000-fold dilution with Tyrode's solution. External solutions were
applied using a home-built, warmed rapid solution exchange device.
2.4. Data analysis
Unless otherwise stated in the text data are presented as
mean±standard error of the mean (SEM). Statistical analysis was
performed using analysis of variance or t-tests as appropriate
(Graphpad, Prism v5). P values of less than 0.05 were taken as
statistically signiﬁcant.
3. Results and discussion
In initial experiments IKir2.1 was elicited by the voltage ramp protocol
shown in Fig. 1Aiii, with representative current traces for WT and
D172N-Kir2.1 current shown respectively in Figs. 1Ai and Aii, in the
absence and presence of 1 mM Ba2+. Fig. 1B shows normalized mean
current–voltage (I–V) data for Ba2+-sensitive WT and D172N IKir2.1. The
I–V relations for WT and mutant Kir2.1 were similar between −120
and−90mVand themean reversal potential (Erev)wasnot signiﬁcantly
different (−88.3±0.5 mV for WT-Kir2.1 versus −89.3±1.1 mV for
D172N-Kir2.1; PN0.05). However, outward IKir2.1 differed markedly
between the two channels: it was signiﬁcantly greater for D172N-Kir2.1
between−80 and−30 mV and in addition peaked at a more positive
membrane potential (Fig. 1B). Co-expressed WT-D172N IKir2.1 exhibited
a similar I–V proﬁle (Fig. 1B) to WT IKir2.1 between−120 and−80 mV
(Erev of −87.6± 0.5 mV; PN0.05 versus WT), with outward current
between −70 and −30 mV that was intermediate in amplitude
between that for individually expressed WT and D172N Kir2.1. These
features are qualitatively consistent with those at ambient temperature
reported previously [2], although the voltage range over which outward
D172N IKir2.1 was signiﬁcantly greater than WT IKir2.1 was wider in the
present study (than a range between−75and−45mVreported in [2]).The results of AP clamp experiments using an epicardial ventricular
AP waveform are shown in Figs. 1C and D. Figs. 1Ci, Cii and Ciii show
Ba2+-sensitive IKir2.1 for WT, WT-D172N and D172N Kir2.1 respectively.
AP commands were applied from a holding potential of −80 mV at
which there was outwardly directed steady-state IKir2.1. Current
markedly decreased following the AP upstroke for each WT and
D172N Kir2.1 expression condition; throughout most of the AP plateau
phase, a small outward current throughWT Kir2.1 was present and this
was also the case for co-expressed WT-D172N and for D172N alone. IK1
channels incorporating Kir2.1 would therefore be anticipated to
contribute a small amount of repolarizing current throughout much of
the AP plateau phase. Towards the latter part of the plateau, outward
current increased for each Kir2.1 expression-condition, with a marked
outward current during terminal repolarization. The outward
current during terminal repolarization of the AP was markedly
greater (∼4.6-fold, Pb0.01) for D172N-Kir2.1 (1.52±0.47 nA; n=11)
than for WT-Kir2.1 (0.33±0.06 nA; n=19), with that for co-expressed
WT-D172N-Kir2.1 being intermediate between the two (0.72±0.12 nA;
n=18;∼2.2 fold that forWT, Pb0.01 versusWT; Pb0.05 versusD172N).
Figs. 1Di–Diii show representative normalized instantaneous I–V
relations for IKir2.1 during the repolarizing phase of the AP command.
Peak outward currentwaspositively shifted by∼+8mVforD172N IKir2.1
(from −68.0±1.0 mV for WT, to −60.3± 2.5 mV for D172N-Kir2.1;
Pb0.01 versusWT) and by∼+4mV for co-expressedWT-D172N-Kir2.1
(to −63.6±1.6 mV; Pb0.05 versus WT; PN0.05 versus D172N). The
larger and earlier IKir2.1 when D172N Kir2.1 was present would be
anticipated to abbreviate AP repolarization in the setting of SQT3.
Additional experiments on singly expressed WT or D172N Kir2.1 using
endocardial and midmyocardial AP commands (data not shown)
showed similar effects of the D172N mutation to those seen with the
epicardial ventricular AP waveform.
AP clamp experiments were also performed using an atrial
AP command waveform. Figs. 2Ai, Aii and Aiii show representative
Ba2+-sensitive IKir2.1 for WT, WT-D172N and D172N Kir2.1 respec-
tively. In the absence of a prominent AP plateau phase, the elicited
current proﬁles differed markedly from those seen with a ventricular
AP command; however, the WT current conﬁguration is similar to
that predicted previously from simulation of IKir2.1 during atrial APs [12],
with IKir2.1 contributing repolarizing current throughoutmuch of the AP
waveform, after the initial rapid repolarization phase. Peak outward
current during repolarization for D172N Kir2.1 (1.22±0.31 nA; n=10)
was ∼3-fold that for WT Kir2.1 (0.39±0.07 nA; n=15; Pb0.01). Peak
outward IKir2.1 during AP repolarization for co-expressed WT-D172N
(0.77±0.16 nA; n=12) was ∼2-fold that for WT IKir2.1 (Pb0.05). Figs.
2Bi, Bii and Biii show representative instantaneous I–V relations for
IKir2.1 during AP repolarization: peak outward current was positively
shifted by +9 mV for D172N IKir2.1 (from −67.8±1.4 mV for WT,
to −58.8±3.1 mV for D172N; Pb0.01). For WT-D172N co-expression,
peak outward IKir2.1 during the atrial AP was shifted by ∼+5 mV
(to−63.2±2.0 mV; n=12; Pb0.05 versusWT; PN0.05 versus D172N).
Thus, our AP clamp ﬁndings are consistent with a greater and earlier
contribution of IK1 channels containing Kir2.1 subunits to repolarization
of both ventricular and atrial APs in SQT3.
The D172 residue is located in a highly conserved region of the
transmembrane pore of the Kir2.1 channel [2] and its mutation has
been reported to inﬂuence channel block by Mg2+ ions and
polyamines [9,13]. The quinolone agent chloroquine blocks potently
native IK1 [14] and has recently been shown to inhibit Kir2.1 by
interacting at a site in the cytoplasmic domain (i.e. distinct from the
transmembrane pore region) of the channel, with residues E224, D259
and E299 being strong binding determinants, F254 also acting as a
(weaker) determinant, whilst the alanine mutant D172A produced a
comparatively small attenuation of chloroquine potency [15]. We
reasoned, therefore, that chloroquinemight be an effective inhibitor of
D172N-Kir2.1 channels. To test this proposition, a range of chloroquine
concentrationswas tested againstWT, D172N-Kir2.1 and co-expressed
Fig. 2. WT, WT-D172N and D172N-Kir2.1: atrial AP clamp and sensitivity to chloroquine. (A) Proﬁle of 1 mM Ba2+-sensitive WT IKir2.1 (Ai), WT-D172N (Aii) and D172N IKir2.1 (Aiii)
(solid traces) during an atrial AP command (dash-dotted trace, 1 Hz). Residual capacitative current transients during the rising phase of the AP command have been blanked for
clarity of display. (B) Instantaneous I–V relations for WT (Bi), WT-D172N (Bii) and D172N (Biii) current during atrial repolarization. For each cell, currents were normalized as for
Fig.1D. Direction of repolarization is denoted by arrows. To facilitate comparison between the different channel expression conditions, theWT I–V curvewas superimposed (as a grey
trace) on the WT-D172N (Bii) and D172N (Biii) IV curves. (C) Representative traces showing the effect of 3 μM chloroquine application on WT IKir2.1 (Ci) and D172N IKir2.1 (Cii),
elicited by ventricular AP command (superimposed). (D) Concentration–response relations for inhibition by chloroquine of maximal outward peak Kir2.1 current elicited during AP
clamp. Data for WT (squares), WT-D172N (circles) and D172N (triangles) IKir2 are shown overlaid (for each expression condition n=4–8 cells per concentration). For IC50 values see
‘Results and discussion’ text.
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tricular AP repolarization was assessed [cf 15], using an identical AP
waveform for each channel/expression condition to enable direct
comparison of observed blocking potency. Figs. 2Ci and Cii show
representative traces of WT and D172N IKir2.1 before and during
exposure to 3 μM chloroquine. Whole-cell current through the two
channels was attenuated by chloroquine to a similar extent. Fig. 2D
contains concentration–response relations for effects of chloroquine
on singly expressed WT and D172N and on co-expressed WT-D172N
IKir2.1, showing these to be similar between the WT and differing
D172N Kir2.1 expression conditions. The half-maximal inhibitory
concentration (IC50) value for WT IKir2.1 was 2.45 μM (95% conﬁdence
interval (C.I.) 2.14 to 2.79 μM; Hill coefﬁcient 1.13±0.07) in fair
agreement with [15]. The observed IC50 value for inhibition of
D172N IKir2.1 was 3.30 μM (95% C.I. from 2.90 to 3.75 μM; Hill
coefﬁcient 1.05± 0.06; PN0.05 versus WT). Chloroquine inhibited co-
expressed WT and D172N IKir2.1 with an IC50 value of 3.11 μM (95% C.I.
2.72 to 3.55 μM; Hill coefﬁcient 1.28±0.10; PN0.05 versus both WT
and D172N alone). As the voltage at which peak IKir2.1 during AP
repolarization occurred was positively shifted for D172N compared to
the WT channel, an additional comparison of blocking potency was
made at a single standardized membrane potential value (−68 mV;
the mean value for peak WT outward current in Fig. 1D). This
comparison (concentration–response relations not shown) also
yielded little variation in blocking potency between WT and mutant
channels, with IC50 values of: 2.91 μM for WT IKir2.1 (95% C.I. 2.46 to
3.45 μM, and not signiﬁcantly different from 2.45 μM; Hill coefﬁcient
1.08±0.08); 3.68 μM for D172N IKir2.1 (95% C.I. from 3.24 to 4.18 μM;
Hill coefﬁcient 1.09±0.07; PN0.05 versus WT) and 3.25 μM for co-
expressed WT-D172N IKir2.1 (95% C.I. 2.77 to 3.80 μM; Hill coefﬁcient
1.1±0.10; PN0.05 versus both WT and D172N alone). Thus, chlor-
oquine produced similar inhibition of IKir2.1 for WT, D172N and co-
expressed WT and D172N Kir2.1.
Chloroquine has been shown previously to block preferentially
outward over inward current for both IK1 and IKir2.1 [14,15] and
this would appear well-suited to reducing consequences of a gain-
of-function mutation that selectively augments outward IKir2.1.
Chloroquine can be anticipated also to inhibit KCNH2-encoded hERG
channel subunits (which underlie native IKr) [e.g. 16] and in additional
experiments (not shown) we found chloroquine to inhibit WT-hERG
channels at overlapping concentrations (IC50 of 2.18 μM; 95% C.I. 1.98
to 2.39 μM; though, in contrast to Kir2.1, blocking potency of the SQT1-
linked N588K-hERG mutation was reduced ∼8.5-fold in our hands;
data not shown). After oral administration, plasma levels of
chloroquine range from ∼1–5 μM (depending on the dose adminis-
tered) and these levels are accompanied by some rate-corrected QT
(QTC) interval prolongation [17]. As IC50 values for chloroquine
inhibition of both Kir2.1 and hERG seen under our conditions (and
cf [15,16]) fall within this clinical range, it seems likely that inhibition
of both these channel types may contribute to observed QTC interval
prolongation. Our data show that the chloroquine sensitivity of WT
and D172N Kir2.1 is similar to one another when tested under
identical conditions. As the QTC interval and, by extension, ventricular
action potential waveform duration in SQT patients differ from those
in normal individuals, it cannot be assumed that the precise level of
Kir2.1 (or hERG) block would be identical in both settings. However,
due to the signiﬁcant overlap between the clinical concentration range
and the concentration range over which these channels are sensitive
to chloroquine, it seems reasonable to propose that both IK1 and IKr in
SQT3 patients would be susceptible to chloroquine inhibition, effectsthat would be anticipated to be synergistic in reducing net repolariz-
ing current. It should be noted that chloroquine is associated with a
range of adverse effects, particularly gastrointestinal problems
(including nausea, vomiting, and diarrhea), lightheadedness and
dizziness [17]. Therefore, chloroquine may not itself be ideal for long-
term administration to normalize QT intervals in SQT3. On the other
hand, chloroquine might represent a template chemical structure
from which more clinically useful Kir2.1 inhibitors could be
developed.
Thus, considered collectively, our ﬁndings provide evidence that
compoundswith chemical structures related to chloroquinemaybe able
to offset abbreviated cardiac AP repolarization caused by augmented
Kir2.1 function. Further work may be warranted to determine the
potency of chloroquine against other Kir2.x isoforms and also whether
or not it is effective against other gain-of-function KCNJ2mutations.
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